Business Context and Reporting Period
This Form 8-K filing by Benitec Biopharma Inc. (BNTC) is dated August 9, 2023. The report addresses the status of the Company's listing on The Nasdaq Stock Market LLC regarding compliance with the minimum bid price requirement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance required for listing compliance.
Material Changes
The Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). Previously, on September 6, 2022, the Company was notified that its common stock bid price had fallen below $1.00 for 30 consecutive business days. As of August 9, 2023, the Company's common stock closing price was at $1.00 per share or greater for 10 consecutive trading days, resulting in the closure of the delisting matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies beyond the resolution of the specific listing deficiency. No unusual items were reported.
Investor Verification Checklist
- Verify the current trading price of BNTC to ensure continued compliance with the $1.00 minimum bid price rule.
- Review the Company's most recent 10-K or 10-Q filings for comprehensive financial data, as this 8-K does not contain financial statements.
- Confirm the Company's ongoing operational status and cash runway through separate regulatory filings or press releases.